Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders

Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Second Quarter Financial Results

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result